Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -40.98 | — | — | 3.41 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.18 | 9.68 | 14.28 | 2.24 | 4.54 | 3.60 | 1.90 | 3.53 | 3.51 | 2.27 | 3.15 | 1.88 | — | — | — | — | — | — | — | — | 7.61 |
| — | +168.8% | +649.5% | -36.4% | +29.3% | +58.8% | -39.6% | +87.4% | — | — | — | — | — | — | — | — | — | — | — | — | +50.4% | |
| P/B Ratio | 1.22 | 1.70 | 2.36 | 1.84 | 1.07 | 7.66 | 2.64 | 3.11 | 3.70 | 2.23 | 2.24 | 1.31 | 1.12 | 1.09 | 0.61 | 0.77 | 0.93 | 0.98 | 0.81 | 0.75 | 0.85 |
| — | -77.9% | -10.7% | -40.8% | -71.0% | +243.3% | +18.2% | +137.1% | +229.7% | +104.1% | +267.2% | +71.1% | +20.5% | +11.4% | -24.8% | +1.7% | +9.9% | +14.0% | -8.5% | -37.0% | -67.3% | |
| P/FCF | — | — | — | 6.71 | — | — | — | — | — | — | — | 0.18 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | 4.10 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 3.68 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.8% | 99.9% | 99.7% | 99.9% | -53.7% | -67.5% | -57.7% | -94.1% | -97.4% | 99.6% | 99.4% | 98.8% | — | — | — | — | — | — | — | — | -195.4% |
| — | +247.9% | +272.8% | +206.2% | +44.9% | -167.8% | -158.0% | -195.2% | — | — | — | — | — | — | — | — | — | — | — | — | -981.7% | |
| Operating Margin | -16.8% | -47.4% | -138.4% | 46.6% | -100.9% | -115.2% | -105.5% | -156.7% | -160.1% | -143.0% | -185.5% | -175.2% | — | — | — | — | — | — | — | — | -301.8% |
| — | +58.8% | -31.2% | +129.7% | +37.0% | +19.4% | +43.1% | +10.5% | — | — | — | — | — | — | — | — | — | — | — | — | -2499.1% | |
| Net Margin | -8.5% | -28.8% | -110.5% | 52.0% | -85.2% | -105.9% | -93.6% | -140.5% | -140.4% | -130.7% | -156.9% | -153.0% | — | — | — | — | — | — | — | — | -300.7% |
| — | +72.8% | -18.1% | +137.0% | +39.3% | +18.9% | +40.3% | +8.2% | — | — | — | — | — | — | — | — | — | — | — | — | -3007.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -5.1% | -1.5% | -4.5% | 11.3% | -9.2% | -45.1% | -29.2% | -34.8% | -31.7% | -33.1% | -24.6% | -26.5% | -29.8% | -27.0% | -24.8% | -24.2% | -20.4% | -18.1% | -14.6% | -30.6% | -8.2% |
| — | +96.6% | +84.6% | +132.6% | +71.1% | -36.0% | -18.4% | -31.5% | -6.2% | -22.9% | +0.6% | -9.4% | -45.9% | -49.3% | -69.4% | +21.0% | -148.2% | -83.4% | -31.2% | -98.5% | -561.3% | |
| ROA | -3.2% | -1.4% | -3.7% | 8.9% | -5.7% | -11.3% | -8.1% | -9.4% | -8.9% | -9.5% | -7.1% | -11.6% | -24.4% | -22.6% | -20.5% | -20.1% | -17.5% | -16.0% | -13.1% | -27.4% | -7.4% |
| — | +88.0% | +54.4% | +194.3% | +35.7% | -19.6% | -14.6% | +18.8% | +63.4% | +58.0% | +65.6% | +42.2% | -39.7% | -41.3% | -57.0% | +26.8% | -137.4% | -83.2% | -34.9% | -104.8% | -560.3% | |
| ROIC | -12.2% | -2.1% | -5.3% | 9.5% | -10.2% | -447.5% | -307.8% | — | -101.4% | -55.5% | -40.9% | -47.6% | -44.2% | -40.6% | -46.4% | -40.2% | -25.4% | -19.7% | -15.0% | -32.4% | -8.3% |
| — | +99.5% | +98.3% | — | +89.9% | -707.0% | -653.4% | — | -129.3% | -36.5% | +12.0% | -18.3% | -73.8% | -106.5% | -208.8% | -24.0% | -206.6% | -98.3% | -35.6% | -125.9% | -456.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.16 | 0.11 | 0.09 | 0.06 | 0.05 | 0.06 | 0.06 | 0.02 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 |
| — | -95.2% | -88.7% | -86.3% | -72.8% | +216.5% | +87.4% | +62.5% | +151.7% | +56.6% | +59.1% | +36.0% | -47.4% | -21.6% | -3.9% | +9.3% | +30.0% | +19.4% | +12.0% | -8.9% | -19.1% | |
| Debt / EBITDA | — | — | — | 0.13 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.22 | 13.99 | 6.65 | 5.22 | 4.44 | 1.64 | 2.05 | 2.42 | 2.36 | 2.74 | 3.02 | 3.41 | 6.96 | 7.26 | 8.00 | 5.95 | 7.44 | 8.31 | 12.21 | 9.59 | 12.61 |
| — | +754.0% | +224.5% | +116.0% | +88.1% | -40.1% | -32.2% | -29.2% | -66.1% | -62.3% | -62.2% | -42.7% | -6.4% | -12.7% | -34.5% | -38.0% | -41.0% | -43.8% | -20.1% | +4.4% | -14.0% | |
| Quick Ratio | 5.22 | 13.99 | 6.65 | 5.22 | 4.44 | 1.64 | 2.05 | 2.42 | 2.36 | 2.74 | 3.02 | 3.41 | 6.96 | 7.26 | 8.00 | 5.95 | 7.44 | 8.31 | 12.21 | 9.59 | 12.61 |
| — | +754.0% | +224.5% | +116.0% | +88.1% | -40.1% | -32.2% | -29.2% | -66.1% | -62.3% | -62.2% | -42.7% | -6.4% | -12.7% | -34.5% | -38.0% | -41.0% | -43.8% | -20.1% | +4.4% | -14.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ASMB stock.
Assembly Biosciences, Inc.'s current P/E is -41.0x. The average P/E over the last 1 quarters is 3.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Assembly Biosciences, Inc.'s current operating margin is -16.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Assembly Biosciences, Inc.'s business trajectory between earnings reports.